You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings
SBC: Discidium Biosciences, LLC Topic: NIAIDAntiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule targeting of NADPH oxidase in neutrophils
SBC: P2D, INC Topic: NHLBIDESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Stabilization of Influenza Vaccine by Silica-Coating
SBC: STONESTABLE, INC. Topic: NIAIDThe goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under ambient environmental conditions Currently vaccines are either stabil ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Star-dots fluorescent nanoparticles for flow cytometry and biomedical imaging
SBC: Nanoscience Solutions, LLC Topic: NIAIDFluorescent nanoparticlesFNPare becoming increasingly popular in biomedical imaging and taggingCompared to molecule based fluorophoresFNP are typically brighter and more photostableThey can be functionalized with more than one tagging moleculeused for the tagging and tracing of specific moleculescellstissuesBrighter fluorescence facilitates more sensitive labelingand in many casesa lower limit of ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Stem Cells for Treating Acute Stroke
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: 999ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Survey and Test Platform for Use in Underserved Populations
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: NEIDESCRIPTION (provided by applicant): Advanced Medical Electronics Corp, in collaboration with the Johns Hopkins University School of Medicine, proposes to develop a hardware/software platform suitable for administering a variety of tests and survey instruments to underserved populations in settings that can range from living rooms to libraries, community centers to nursing homes, and from inner ci ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeted Polymer Micelles for Treatment of Metastatic Melanoma
SBC: INTEZYNE TECHNOLOGIES, INC. Topic: NCIDESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.
SBC: EARNANO LLC Topic: NICHDOtitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Technology Transfer of the ATLAS and ATHENA Programs
SBC: Odyssey Science Innovations, LLC Topic: NIDADESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health